Trials / Completed
CompletedNCT00259883
Combination Of PAXIL Tablet And Benzodiazepines
Post-marketing Clinical Study on PAXIL Tablet in Patients With Depression or Depressive Mood - A Study on Combination of PAXIL Tablet and Benzodiazepines
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to assess the efficacy and safety of combination therapy of PAXIL and benzodiazepine anxiolytics. PAXIL Tablet will be administered to patients with depression or depressive episodes who have received Benzodiazepines for at least 4 weeks, and changes in the symptoms of depression will be evaluated by use of the rate and extent of decrease in Hamilton Rating Scale for Depression (HAM-D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paroxetine | 1 or 2 tablets once a day |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2006-02-01
- Completion
- 2006-02-01
- First posted
- 2005-12-01
- Last updated
- 2017-01-18
Source: ClinicalTrials.gov record NCT00259883. Inclusion in this directory is not an endorsement.